EE495 Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression

Abstract

Adjuvant atezolizumab vs. best-supportive care (BSC) after complete resection and adjuvant platinum-based chemotherapy in patients with early-stage resected non-small cell lung cancer (NSCLC) was evaluated in IMpower010 trial, showing an improvement in disease-free survival (DFS) in favor of atezolizumab. We aimed to assess the cost-effectiveness of adjuvant atezolizumab in the treatment of early-stage NSCLC patients (stage II-IIIA) with expression of programmed death-ligand 1 PD-L1≥50% without mutations in EGFR or ALK rearrangements in Spain.